| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/28/2005 | WO2005068632A1 EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME |
| 07/28/2005 | WO2005068504A1 Inflammatory cytokine inhibitor |
| 07/28/2005 | WO2005068493A1 Anthrax vaccine in the form of a spore |
| 07/28/2005 | WO2005067994A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/28/2005 | WO2005067981A1 Gene therapy for tumor using minus-strand rna virus vector encoding immunostimulating cytokine |
| 07/28/2005 | WO2005067980A2 Design of therapeutics and therapeutics |
| 07/28/2005 | WO2005067968A1 Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| 07/28/2005 | WO2005067967A1 Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion) |
| 07/28/2005 | WO2005067966A1 Methods for tailoring the immune response to an antigen or immunogen |
| 07/28/2005 | WO2005067963A1 Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
| 07/28/2005 | WO2005067620A2 ANTIBODIES TO MAdCAM |
| 07/28/2005 | WO2005067543A2 Murine calicivirus |
| 07/28/2005 | WO2005067477A2 Anti-human lymphotoxin alpha antibodies, compositions, methods and uses |
| 07/28/2005 | WO2005067460A2 Epha2 vaccines |
| 07/28/2005 | WO2005056024A9 Methods of enhancing stem cell engraftment |
| 07/28/2005 | WO2005051983A3 Oligomeric complexe formation of recombinant multi subunit chimeric polypeptides |
| 07/28/2005 | WO2005049074A3 Methods for modulating the th2 immuneresponse to an antigen by adding or removing activated carbonyl groups from the antigen |
| 07/28/2005 | WO2005047328A3 Antibodies against secretoryleukocyte protease inhibitor |
| 07/28/2005 | WO2005045062A3 Gene expression and polymorphisms associated with lung cancer |
| 07/28/2005 | WO2005042581A3 Modified anti-cd52 antibody |
| 07/28/2005 | WO2005037867B1 ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| 07/28/2005 | WO2005035557A3 Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| 07/28/2005 | WO2005030935A3 Adjuvant activities of mutants of lt-iia and lt-iib enterotoxin lacking binding to ganglioside |
| 07/28/2005 | WO2005030931A3 Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent |
| 07/28/2005 | WO2005025516A3 Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| 07/28/2005 | WO2005021730A3 Biodegradable polymer-ligand conjugates and their uses in isolation of cellular subpopulations and in cryopreservation, culture and transplantation of cells |
| 07/28/2005 | WO2005012339A3 Immunogenic protein and uses thereof |
| 07/28/2005 | WO2005009366A3 Restoring vascular function |
| 07/28/2005 | WO2005004793A3 Compositions and methods for treating coagulation related disorders |
| 07/28/2005 | WO2005001033A3 Tolerance induction and maintenance in hematopoietic stem cell allografts |
| 07/28/2005 | WO2004050900A3 Compositions, splice variants and methods relating to colon specific genes and proteins |
| 07/28/2005 | WO2003105750A3 Antigen-presenting cells for neuroprotection and nerve regeneration |
| 07/28/2005 | WO2003103597A3 Methods of diagnosing & treating diabetes and insulin resistance |
| 07/28/2005 | WO2003099196A3 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| 07/28/2005 | WO2003072035A8 Compositions and methods for the treatment of immune related diseases |
| 07/28/2005 | WO2002055010A3 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/28/2005 | US20050166290 Expression cassettes and methods for delivery of animal vaccines |
| 07/28/2005 | US20050166274 Compositions and methods for the diagnosis and treatment of tumor |
| 07/28/2005 | US20050165348 Needleless syringe using supersonic gas flow for particle delivery |
| 07/28/2005 | US20050164988 Bisphosphate, bis-quaternary ammonium or bis-amine salt compounds that bind a Toll-like receptor; use desensitizing allergies, treating autoimmune diseases and inflammatory diseases, ischemia |
| 07/28/2005 | US20050164313 Methods and compositions for the detection of cervical cancer |
| 07/28/2005 | US20050164305 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 07/28/2005 | US20050164298 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor(ghs) |
| 07/28/2005 | US20050164267 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 07/28/2005 | US20050164263 identification of amino acid sequences and proteins related to MAP/ERK subfamily; gene chip; transgenic nonhuman animal; nucleic acid vector; expression in larynx epithelium, Wilms' tumors of the kidney, pancreas adenocarcinomas, fetal brain, and hippocampus; models for human therapeutic targets |
| 07/28/2005 | US20050164222 Optimization of immunomodulatory properties of genetic vaccines |
| 07/28/2005 | US20050164176 Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| 07/28/2005 | US20050164175 Respiratory Syncytial Virus; vectors containing heterogeneity genes |
| 07/28/2005 | US20050164170 Neurovirulent strain of the west nile virus and uses thereof |
| 07/28/2005 | US20050164166 Expression vector comprising nucleotide sequences coding immunoglobulin-envelope protein fusion; immunotherapy; viricides |
| 07/28/2005 | US20050164164 Hiv-1 virus tat-protein mutants |
| 07/28/2005 | US20050163832 liposome, safe and efficient delivery of agents, i.e. proteins, nucleic acids, small molecules and/or other drugs, into cell of higher organism in vitro or in vivo; transducing polypeptide-lipid vesicle complex; protein transduction domain of HIV-1 TAT protein, VP22 herpes virus or Antennapedia protein |
| 07/28/2005 | US20050163810 Methods for the reduction of malignant tumors by an eosinophil/helminth therapy |
| 07/28/2005 | US20050163808 Group A streptococcal polysaccharide immunogenic compositions and methods |
| 07/28/2005 | US20050163806 Immune stimulating and controlling composition comprising bacterial chromosomal dna fragments and non-toxic lipopolysaccharides |
| 07/28/2005 | US20050163805 Orthopoxvirus vectors, genes and products thereof |
| 07/28/2005 | US20050163804 Containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus; Japanese encephalitis virus (JEV), West Nile virus (WNV) or related flaviviruses |
| 07/28/2005 | US20050163803 Non-animal origin stabilizers and processes for producing the same |
| 07/28/2005 | US20050163797 Also comprises neuroactive compounds, hormones, compounds having growth hormone acitivity, and polypeptide; vaccines; selected HCV antigens together with the polyamino acid adjuvants, especially polyarginine, and optionally the immunogenic compounds |
| 07/28/2005 | US20050163796 Decapeptide immunogen able inducing cytotoxic lymphocytes, is used to provide a protection against an HIV infection; biodrugs |
| 07/28/2005 | US20050163795 IHNV G protein for immune stimulation |
| 07/28/2005 | US20050163794 Immunological herpes simplex virus antigens and methods for use thereof |
| 07/28/2005 | US20050163793 Methods for recovering peptides from stress protein-peptide complexes |
| 07/28/2005 | US20050163792 Stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen |
| 07/28/2005 | US20050163791 Brachyspira hyodysenteriae vaccine |
| 07/28/2005 | US20050163788 Prevention and treatment of amyloidogenic disease |
| 07/28/2005 | US20050163787 Immunological adjuvant |
| 07/28/2005 | US20050163786 Compounds and methods for modulating adhesion molecule function |
| 07/28/2005 | US20050163785 affect cell growth by blocking progression of the cell cycle in G2/M and their use in therapy of cancers which express the antigen |
| 07/28/2005 | US20050163783 polypeptide dimers having at least four binding sites and at least two polypeptide chains linked via at least one interchain disulfide linkage; IgG3 hinge domain |
| 07/28/2005 | US20050163782 polypeptide dimers having at least four binding sites and at least two polypeptide chains linked via at least one interchain disulfide linkage; IgG3 hinge domain |
| 07/28/2005 | US20050163778 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/28/2005 | US20050163776 Treatment of tse infection |
| 07/28/2005 | US20050163775 selectively deplete B cells from a mixed population of cells by contacting with a BAFF antagonist and a CD20 antigen binding antibody; immunoadhesin; treating B cell malignancies or a B-cell regulated autoimmune disorder |
| 07/28/2005 | US20050163772 B7S1: an immune modulator |
| 07/28/2005 | US20050163770 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 07/28/2005 | US20050163768 For immunization against cancer of epithelial origin and against small cell lung cancer, immunization against HIV-infections; murine internal image anti-idiotypic antibodies (Ab2) to monoclonal antibodies BR55-2 (Ab1) |
| 07/28/2005 | US20050163762 activating auto-antigen specific T cells such as AChR-specific T cells in an auto-immune disease patient such as myasthenia gravis; virus for transferring genes to antigen presenting cells so that they express, process, and present an antigen which will stimulate antigen-specific T cells |
| 07/28/2005 | US20050163747 Heteromultimeric TNF ligand family members |
| 07/28/2005 | US20050163745 Immunogens; polyesters; glycolic acid-lactic acid copolymers; vaccines; delayed release; mucosal/parenteral administration |
| 07/28/2005 | US20050163744 Novel method for down-regulation of amyloid |
| 07/28/2005 | US20050163707 Radio labelled monoclonal antibody human milk fat globule1, binds selectively to polymorphic epithelial mucin; Taxotere chemotherapeutic agent; administered in combination |
| 07/28/2005 | DE202005001888U1 Antitumor composition comprises interleukin-2 and sodium dodecyl sulfate in the form of microaggregates |
| 07/28/2005 | CA2554001A1 Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same |
| 07/28/2005 | CA2553947A1 Promoter |
| 07/28/2005 | CA2553609A1 Methods and compositions for modulating a steroid receptor |
| 07/28/2005 | CA2553594A1 Particle-induced ghrelin immune response |
| 07/28/2005 | CA2553377A1 Gene therapy for tumors using minus-strand rna viral vectors encoding immunostimaulatory cytokines |
| 07/28/2005 | CA2552523A1 Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam) |
| 07/28/2005 | CA2552004A1 Methods for tailoring the immune response to an antigen or immunogen |
| 07/28/2005 | CA2551121A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/27/2005 | EP1557466A1 Tumor antigen protein and utilization thereof |
| 07/27/2005 | EP1557462A2 Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| 07/27/2005 | EP1557432A2 Hybrid proteins which form heterodimers |
| 07/27/2005 | EP1557428A1 Antibodies against a human stromal derived factor (SDF) and pharmaceutical composition containing them |
| 07/27/2005 | EP1557177A1 Antigen for transcutaneous immunisation |
| 07/27/2005 | EP1557172A1 Method and composition for regulating the activity of regulatory t cells |
| 07/27/2005 | EP1557171A1 Rabbit skin comprising biological active substance and its use |
| 07/27/2005 | EP1556513A2 Compositions and methods for treating human papillomavirus-mediated disease |
| 07/27/2005 | EP1556493A1 Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof |